At Xiogenix, John was part of a dynamic leadership team that included Rachel Bahr and Jerry Jendusa, from whom he gained invaluable insights. Together, they propelled Xiogenix to new heights, nurturing a culture of collaboration and innovation. This team-centric approach led to significant advancements in bioscience, particularly in tissue banking and cell therapy, showcasing the power of collective effort in achieving corporate success and industry breakthroughs.

Tonny Voermans, President of BioMed, expressed enthusiasm about John’s appointment, stating, “We are thrilled to welcome John to our team. His experience in harnessing the strength of collaborative leadership and his proven track record in the bioscience field are exactly what BioMed needs to enhance our presence and impact in the U.S. ENT market.”

In his new role, John is tasked with driving BioMed’s business development initiatives in the United States, focusing on introducing innovative solutions that address the complex needs of the ENT healthcare sector. His leadership is anticipated to foster a culture of innovation and teamwork, mirroring the successful strategies employed at Xiogenix.

“I am excited to join BioMed and contribute to its mission of advancing ENT healthcare through innovation,” said John Reimer. “The opportunity to lead the U.S. operations and work with a talented team to deliver impactful solutions is incredibly motivating. I look forward to building on the collaborative leadership approach I experienced at Xiogenix to achieve great things at BioMed.”

BioMed is dedicated to improving patient outcomes and enhancing the efficiency of ENT healthcare services with its cutting-edge solutions. With John Reimer at the helm of its U.S. business development, the company is poised for significant growth and continued innovation in the ENT field.